Adding Menin Inhibitor Promising in Certain AML Patients

(MedPage Today) — Adding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML), according to results…